Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients (MM)

Al-Rasheed University College

Status and phase: Withdrawn; Phase 4

Conditions: Newly Diagnosed Multiple Myeloma

Treatments: Drug: Bortezomib 3.5 MG

Study type: Interventional

Funder types: Other

Identifiers

NCT04348006

AR200103

SEANM (Registry Identifier)

Details and patient eligibility

About

Bortezomib considered the standard of care for treating multiple myeloma patients, the aim was to assess the safety and efficacy of newly approved drug (Alvocade ®) in Iraq, in newly diagnosed patients.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosis Multiple myeloma with CRAB (C: hypercalcemia, R: renal impairment, A: anemia, and B: bone lesions)
• Age above 18 years old

Exclusion criteria

• Age below 18 years
• Smoldering MM

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Induction Therapy

Experimental group

Description:

Bortezomib will be administered as part of VCD or VRD protocols

Treatment:

Drug: Bortezomib 3.5 MG